Bibliographic Details
| Title: |
Real-world experience on intravitreal dexamethasone implant in patients with macular edema scheduled to undergo cataract surgery |
| Authors: |
Chun-Chieh Lai, Shu-Chun Kuo |
| Source: |
BMC Ophthalmology, Vol 23, Iss 1, Pp 1-8 (2023) |
| Publisher Information: |
BMC, 2023. |
| Publication Year: |
2023 |
| Collection: |
LCC:Ophthalmology |
| Subject Terms: |
Dexamethasone implant, Diabetic macular edema, Sustained release, Cataract, Retinal vein occlusion, Ophthalmology, RE1-994 |
| More Details: |
Abstract Background Patients with pre-existing macular edema (ME) due to diabetes and retinal vein occlusions (RVO) make up a growing population receiving cataract surgery. Surgery is associated with an increased risk of worsening existing ME due to post-surgical inflammation that can be further exacerbated by pre-existing diabetic retinopathy (DR) and retinal vein occlusion. This study aimed to examine the pre-operative use of intravitreal dexamethasone (DEX) implants in patients with ME undergoing cataract surgery. Methods A retrospective study was conducted at National Cheng Kung University Hospital in Taiwan involving 19 eyes of 16 patients with DME or ME associated with RVO. All participants received a DEX implant at baseline and underwent phacoemulsification within 3 months after its insertion. Best-corrected visual acuity (BCVA), intraocular pressure (IOP) and central subfield thickness (CST) were evaluated. Results DEX implants reduced the CST from baseline (357.8 μm) to pre-surgery (280.8 μm). This reduction below baseline continued to month 6 post-surgery (319.4 μm). From baseline (16.15 mmHg), the mean IOP initially increased pre-surgery (17.78 mmHg) before returning to the baseline value at month 6 post-surgery (16.15 mmHg). All patients improved their BCVA from logMAR 0.943 on average at baseline to logMAR 0.532 at month 6 post-surgery. Conclusions The results of the study suggested that patients with ME could benefit from DEX implants before cataract surgery within 3 months to achieve sufficient postoperative inflammation management and limit ME deterioration. DEX implants did not increase IOP post-surgery and was similar to baseline levels. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
1471-2415 |
| Relation: |
https://doaj.org/toc/1471-2415 |
| DOI: |
10.1186/s12886-023-03093-y |
| Access URL: |
https://doaj.org/article/f1a51653a2bf42abae20ffd4719bb35f |
| Accession Number: |
edsdoj.f1a51653a2bf42abae20ffd4719bb35f |
| Database: |
Directory of Open Access Journals |
